Evaluation of Drug Pricing Policies under a Potential Reconciliation Package

With Republican control of the White House, Senate and House of Representatives in 2025, it is widely anticipated that the new GOP Congressional majorities will leverage the budget reconciliation process to enact many of their priorities without the need for bipartisan support from Democrats.

encompassing a range of drug pricing and supply chain policy proposals from the 118th Congress to assess which of these might be eligible for enactment through the budget reconciliation process. Of the 40 pieces of legislation reviewed, only 12 of these bills (consisting of nine policies) appear to be appropriate for reconciliation at this time.
 
to view the table which also describes the policies and relevant legislation, a CBO estimate (if one exists), the health insurance markets to which these policies would apply, and our assessment of whether these are appropriate for reconciliation.